全国同城凤凰楼信息茶楼_51pcmc品茶2024官网_全国兼职凤凰楼信息

Biography

Kan Ding, Professor, Ph.D., supervisor, Principal Investigator, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Vice Chairman of Degree Committee of Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Executive Vice Director of Zhongshan Institute of Materia Medica Innovation. He was granted as the National Natural Science Foundation Distinguished Young Scholars of China in 2011. Dr. Kan Ding’s research interest mainly focuses on the structure and function, structure-activity relationship, targeting, and the mechanism underlying action of polysaccharides from traditional Chinese medicine, interaction between bioactive polysaccharide and gut microbiota, and functional mechanism of cell membrane proteoglycan and its related enzymes. In addition, he also tries to discover new target for glycan-based drug discovery and engage in carbohydrate based drug development. At present, there are 25 members in his group in this institute.

Dr. Kan Ding got his M. Sc. degree in pharmacognosy in 1996 in China Pharmaceutical University, and achieved Ph. D. degree in organic chemistry in 1999 in Shanghai Institute of Materia Medica, Chinese academy of sciences. In 1999, he did his postdoctoral training in Lund University in Sweden. Since 2001, he worked as a postdoctoral research fellow associate in University of California, Irvine and a research fellow in Massachusetts General Hospital, Harvard Medical School in U. S. A. During the postdoctoral training, he embarked on the glycobiology study on the structure and function of cell membrane proteoglycan in tumor. In the end of 2005, he was recruited as a full professor by Shanghai Institute of Materia Medica, Chinese academy of sciences. He succeeded in the grant application of National Science Fund for Distinguished Young Scholars of China in 2011.

So far, he has obtained 30 grants, including State Key Program of National Natural Science of China, the National Natural Science Foundation of Science Fund for Distinguished Young Scholars, National Natural Science Foundation, Major National Science and Technology projects: Major New Drug Candidate Drugs, National Science and Technology Major Projects for Key Techniques, Strategic Priority Research Program of the Chinese Academy of Sciences, National High-Tech R&D Program of China, etc., and took part in 9 projects including National Program on Key Basic Research Project (973 Program) and Key projects of the Ministry of Science and Technology. In addition, one book entitled “The structure, function   and action mechanism of polysaccharides from traditional Chinese medicine” has been issued under his general editorship. He also published three chapters in Advanced Medicinal Chemistry and the Extraction and Separation of Active Components in Traditional Chinese Medicine. He has published 160 papers, including on international journal, such as J. Hepatol., Angew. Chem. Int. Ed. Engl., J. Am. Chem. Soc., J. Cell Biol., Carbohydr. Polym., etc. The achievements have been granted 64 national international patents (2 international PCT patents, one patent from the United States, Europe and Japan), the second prize of Natural Science awarded by the Chinese Academy of Sciences, the third Prize of Shanghai Science and Technology Progress Award and the first prize of Guangdong Science and Technology Award.

Research Directions

Dr. Kan Ding’s research interest mainly focuses on the structure and function, structure-activity relationship, targeting molecular discovery and action mechanism of polysaccharides from traditional Chinese medicine, relationship between bioactive polysaccharide and gut microbiota, and functional mechanism of cell membrane proteoglycan and its related enzymes. In addition, he is also trying to discover new target for glycan-based drug discovery and engaging in carbohydrate based new drug development.

Achievements

1. Structure and function of Glce

2. Function of MicroRNAs in angiogenesis probed by glycans

3.Targets discovery of polysaccharide and the underlying mechanism

4. The effects and the mechanism of anti-angiogenesis polysaccharides

5. The mechanism underlying polysaccharide uptake in intestinal cells

Publications

1. He F#, Jiang H#, Peng C, Wang T, Xiao R, Chen M, Song L, Du Z, Wang H, Ding X, Shao Y, Fang J, Zang Y, Hua R*, Li J*, Ding K*. Hepatic Glucuronyl C5-epimerase combats obesity via stabilizing GDF15. J Hepatol. Accepted on Oct 26^th, 2022.

2. Hu C, Wu S, He F, Cai D, Xu Z, Ma W, Liu Y, Wei B*, Li T*, Ding K*. Convergent Synthesis and Anti-Pancreatic Cancer Cell Growth Activity of a Highly Branched Heptadecasaccharide from Carthamus tinctorius. Angew Chem Int Ed Engl. 2022, 61(32): e202202554.

3. Li M#, Li S#, Guo X#, Guo C, Wang Y, Du Z, Zhang Z, Xie C*, Ding K*. Discrete genetic loci in human gut Bacteroides thetaiotaomicron confers pectic glycan metabolism. Carbohydr Polym. 2021. 272:118534.

4. Yao Y, Zhou L, Liao W，Chen H, Du Z, Shao C, Wang P*, Ding K*, HH1-1, a novel Galectin-3 inhibitor, exerts anti-pancreatic cancer activity by blocking Galectin-3/EGFR/AKT/FOXO3 signaling pathway. Carbohydr Polym. 2019, 15;204:111-123.

5. Zhang L#, Wang P#, Qin Y, Cong Q, Shao C, Du Z, Ni X, Li P*, Ding K*. RN1, a novel galectin-3 inhibitor, inhibits pancreatic cancer cell growth in vitro and in vivo via blocking galectin-3 associated signaling pathways. Oncogene. 2017, 36(9):1297-1308.

6. Chen H#, Cong Q#, Du Z, Liao W, Zhang L, Yao Y, Ding K*. Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling. Cancer Lett. 2016 382(1):44-52.

7. Xiao F, Qiu H, Cui H, Ni X, Li J, Liao W, Lu N, Ding K*. MicroRNA-885-3p inhibits the growth of HT-29 colon cancer cell xenografts by disrupting angiogenesis via targeting BMPR1A and blocking BMP/Smad/Id1 signaling. Oncogene, 2015, 34(15):1968-78.

8. Qin Y, Ke J*, Gu X, Fang J, Wang W, Cong Q, Li J, Tan J, Brunzelle JS, Zhang C, Jiang Y, Melcher K, Li JP, Xu HE*, Ding K*. Structural and functional study of D-glucuronyl C5-epimerase. J Biol Chem. 2015, 290(8):4620-30.

9. Liu H, Zhou L, Shi S, Wang Y, Ni X, Xiao F, Wang S, Li P*, Ding K*. Oligosaccharide G19 inhibits U-87 MG human glioma cells growth in vitro and in vivo by targeting epidermal growth factor (EGF) and activating p53/p21 signaling. Glycobiology, 2014 24(8):748-65.

10. Shen X, Fang J, Lv X, Pei Z, Wang Y, Jiang S, Ding K*. Heparin impairs angiogenesis through inhibition of MicroRNA-10b. J Biol Chem. 2011, 286(30):26616-27.